En Carta Diagnostics develops at-home molecular diagnostic tests combining lab-grade PCR accuracy with the simplicity of a rapid test, starting with Lyme disease and STIs.
Create a free EquityFlow account to see En Carta Diagnostics's 2 funding rounds, 5 investors, 12 similar companies.
Sign up free → Sign in